SEARCH

SEARCH BY CITATION

References

  • 1
    Jemal A,Siegel R,Ward E,Murray T,Xu J,Smigal C,Thun MJ. Cancer statistics, 2006. CA Cancer J Clin 2006; 56: 10630.
  • 2
    Stein JP,Lieskovsky G,Cote R,Groshen S,Feng AC,Boyd S,Skinner E,Bochner B,Thangathurai D,Mikhail M,Raghavan D,Skinner DG. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001; 19: 66675.
  • 3
    Watanabe T,Inoue S,Hiroi H,Orimo A,Kawashima H,Muramatsu M. Isolation of estrogen-responsive genes with a CpG island library. Mol Cell Biol 1998; 18: 4429.
  • 4
    Tsuchiya F,Ikeda K,Tsutsumi O,Hiroi H,Momoeda M,Taketani Y,Muramatsu M,Inoue S. Molecular cloning and characterization of mouse EBAG9, homolog of a human cancer associated surface antigen: expression and regulation by estrogen. Biochem Biophys Res Commun 2001; 284: 210.
  • 5
    Suzuki T,Inoue S,Kawabata W,Akahira J,Moriya T,Tsuchiya F,Ogawa S,Muramatsu M,Sasano H. EBAG9/RCAS1 in human breast carcinoma: a possible factor in endocrine-immune interactions. Br J Cancer 2001; 85: 17317.
  • 6
    Akahira JI,Aoki M,Suzuki T,Moriya T,Niikura H,Ito K,Inoue S,Okamura K,Sasano H,Yaegashi N. Expression of EBAG9/RCAS1 is associated with advanced disease in human epithelial ovarian cancer. Br J Cancer 2004; 90: 2197202.
  • 7
    Takahashi S,Urano T,Tsuchiya F,Fujimura T,Kitamura T,Ouchi Y,Muramatsu M,Inoue S. EBAG9/RCAS1 expression and its prognostic significance in prostatic cancer. Int J Cancer 2003; 106: 31015.
  • 8
    Aoki T,Inoue S,Imamura H,Fukushima J,Takahashi S,Urano T,Hasegawa K,Ogushi T,Ouchi Y,Makuuchi M. EBAG9/RCAS1 expression in hepatocellular carcinoma: correlation with tumour dedifferentiation and proliferation. Eur J Cancer 2003; 39: 155261.
  • 9
    Ogushi T,Takahashi S,Takeuchi T,Urano T,Horie-Inoue K,Kumagai J,Kitamura T,Ouchi Y,Muramatsu M,Inoue S. Estrogen receptor-binding fragment-associated antigen 9 is a tumor-promoting and prognostic factor for renal cell carcinoma. Cancer Res 2005; 65: 37006.
  • 10
    Ikeda K,Sato M,Tsutsumi O,Tsuchiya F,Tsuneizumi M,Emi M,Imoto I,Inazawa J,Muramatsu M,Inoue S. Promoter analysis and chromosomal mapping of human EBAG9 gene. Biochem Biophys Res Commun 2000; 273: 65460.
  • 11
    Epstein JI,Amin MB,Reuter VR,Mostofi FK. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 1998; 22: 143548.
  • 12
    Engelsberg A,Hermosilla R,Karsten U,Schulein R,Dorken B,Rehm A. The Golgi protein RCAS1 controls cell surface expression of tumor-associated O-linked glycan antigens. J Biol Chem 2003; 278: 229983007.
  • 13
    Sonoda K,Nakashima M,Kaku T,Kamura T,Nakano H,Watanabe T. A novel tumor-associated antigen expressed in human uterine and ovarian carcinomas. Cancer 1996; 77: 15019.
  • 14
    Nakashima M,Sonoda K,Watanabe T. Inhibition of cell growth and induction of apoptotic cell death by the human tumor-associated antigen RCAS1. Nat Med 1999; 5: 93842.
  • 15
    Xue W,Zender L,Miething C,Dickins RA,Hernando E,Krizhanovsky V,Cordon-Cardo C,Lowe SW. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007; 445: 65660.
  • 16
    Qin XQ,Tao N,Dergay A,Moy P,Fawell S,Davis A,Wilson JM,Barsoum J. Interferon-beta gene therapy inhibits tumor formation and causes regression of established tumors in immune-deficient mice. Proc Natl Acad Sci U S A. 1998; 95: 1441116.
  • 17
    Suzuki K,Nakazato H,Matsui H,Hasumi M,Shibata Y,Ito K,Fukabori Y,Kurokawa K,Yamanaka H. NK cell-mediated anti-tumor immune response to human prostate cancer cell. PC-3: immunogene therapy using a highly secretable form of interleukin-15 gene transfer. J Leukoc Biol 2001; 69: 5317.
  • 18
    Dickinson AJ,Fox SB,Persad RA,Hollyer J,Sibley GN,Harris AL. Quantification of angiogenesis as an independent predictor of prognosis in invasive bladder carcinomas. Br J Urol 1994; 74: 7626.
  • 19
    Pellinen T,Ivaska J. Integrin traffic. J Cell Sci 2006; 119: 372331.
  • 20
    Julien S,Adriaenssens E,Ottenberg K,Furlan A,Courtand G,Vercoutter-Edouart AS,Hanisch FG,Delannoy P,Le Bourhis X. ST6GalNAc I expression in MDA-MB-231 breast cancer cells greatly modifies their O-glycosylation pattern and enhances their tumourigenicity. Glycobiology 2006; 16: 5464.
  • 21
    Reimer TA,Anagnostopoulos I,Erdmann B,Lehmann I,Stein H,Daniel P,Dorken B,Rehm A. Reevaluation of the 22–1-1 antibody and its putative antigen. EBAG9/RCAS1, as a tumor marker. BMC Cancer 2005; 5: 47.
  • 22
    Shariat SF,Karakiewicz PI,Ashfaq R,Lerner SP,Palapattu GS,Cote RJ,Sagalowsky AI,Lotan Y. Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy. Cancer 2008; 112: 31525.